AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8857073
Drug: Hydrogel-type formulation
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel-type formulation of FK613
Trial: 25637937
Drug: Olmesartan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan with ACE inhibitors and β-blockers
Trial: 25637937
Drug: Control with
RxNorm normalized name: Azo Bladder Control With Go Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control with ACE inhibitors and β-blockers
Trial: 21843836
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard doses of oral corticosteroids and physiotherapy limited to airway clearance techniques and breathing exercises)
Trial: 17604664
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microg twice daily
Trial: 17604664
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 330 microg twice daily
Trial: 17315803
Drug: Prompt L-Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L-Pop + F2000
Trial: 8808724
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg i.v. bolus of ondansetron
Trial: 8808724
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg i.v. granisetron
Trial: 8808724
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg i.v. tropisetron
Trial: 8808724
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further antiemetic therapy)
Trial: 3936091
Drug: Caffeine (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (0 mg/kg) + Diazepam (0.15 mg/kg)
Trial: 3936091
Drug: Caffeine (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (0 mg/kg) + Diazepam (0.30 mg/kg)
Trial: 3936091
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) + Diazepam (0.15 mg/kg)
Trial: 3936091
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) + Diazepam (0.30 mg/kg)
Trial: 3936091
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg) + Diazepam (0.15 mg/kg)
Trial: 3936091
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg) + Diazepam (0.30 mg/kg)
Trial: 28815560
Drug: Lindioil ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindioil ointment containing 200 μg g‐1 of indirubin
Trial: 28815560
Drug: Lindioil ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindioil ointment containing 100 μg g‐1 of indirubin
Trial: 28815560
Drug: Lindioil ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindioil ointment containing 50 μg g‐1 of indirubin
Trial: 28815560
Drug: Lindioil ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lindioil ointment containing 10 μg g‐1 of indirubin
Trial: 24140226
Drug: Antidepressants (MED)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (MED)
Trial: 24140226
Drug: Combined CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CBT and antidepressants (COMB)
Trial: 22648221
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (novel anti-acne/anti-aging formulation)
Trial: 22648221
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (tretinoin cream 0.025%)
Trial: 18666803
Drug: Irbesartan therapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan therapy for 9 weeks
Trial: 18666803
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy for 9 weeks
Trial: 16613662
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 200 mg/m2 daily for 5 days
Trial: 16613662
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg (increased to 90 mg for initial serum calcium > or = 13.5 mg/dL) followed by placebo infusions for 4 days
Trial: 16613662
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg for initial serum calcium > or = 13.5 mg/dL
Trial: 16613662
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg for initial serum calcium > or = 13.5 mg/dL
Trial: 16613662
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate for initial serum calcium > or = 13.5 mg/dL
Trial: 14616318
Drug: Mivacurium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.1 mg kg‐1 bolus followed by continuous infusion)
Trial: 11018164
Drug: long-long regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-long regimen (zidovudine starting at 28 weeks' gestation, 6 weeks treatment in infant)
Trial: 11018164
Drug: long-short regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long-short regimen (zidovudine starting at 28 weeks' gestation, 3 days treatment in infant)
Trial: 11018164
Drug: short-long regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-long regimen (zidovudine starting at 35 weeks' gestation, 6 weeks treatment in infant)
Trial: 11018164
Drug: short-short regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-short regimen (zidovudine starting at 35 weeks' gestation, 3 days treatment in infant)
Trial: 10148407
Drug: Rotorest Kinetic
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotorest Kinetic Treatment Table
Trial: 6660456
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position after bupivacaine administration
Trial: 6660456
Drug: Supine position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine position after bupivacaine administration
Trial: 29998882
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) for 12 weeks followed by Peg-IFN for 48 weeks (sequential treatment)
Trial: 27154394
Drug: Enterovirus quantity
RxNorm normalized name: human enterovirus A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterovirus quantity at the time of OPV administration
Trial: 20102858
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (family-centered program with 12 sessions of behavioral curriculum, dietary advice from a registered dietitian weekly for the first 3 months and monthly thereafter, and monthly consultations with a primary care physician)
Trial: 20102858
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly consultations with a primary care physician who received brief training on obesity)
Trial: 16787761
Drug: 1% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diclofenac gel
Trial: 16787761
Drug: Diclofenac tablets
RxNorm normalized name: diclofenac Oral Tablet
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac tablets
Trial: 16787761
Drug: Paracetamol tablets
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol tablets
Trial: 7478700
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral tramadol
Trial: 12386639
Drug: Methylprednisolone alone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone alone (0.3 mg/kg)
Trial: 12386639
Drug: Diltiazem alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem alone (180 mg)
Trial: 12386639
Drug: Methylprednisolone-diltiazem combination
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone-diltiazem combination
Trial: 7845114
Drug: Pulsed intrope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed intrope therapy (PIT) with dobutamine, infused to raise heart rate to 70-80% maximum for 30 min per day, 4 days per week for 3 weeks
Trial: 7845114
Drug: Pulsed intrope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed intrope therapy (PIT) with dobutamine
Trial: 44632
Drug: Flunitrazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (2 mg on the night before operation followed by 2 mg on the morning of operation)
Trial: 23506216
Drug: NeuroAiD (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroAiD (four capsules three times daily for three months)
Trial: 23506216
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four capsules three times daily for three months)
Trial: 17846459
Drug: Feedback on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback on daily step counts (monitoring and recording step counts during week 1)
Trial: 15025611
Drug: 27-G (0.41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27-G (0.41 mm) Quincke spinal needle
Trial: 15025611
Drug: 27-G (0.41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27-G (0.41 mm) Whitacre spinal needle
Trial: 22147094
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4)
Trial: 24161160
Drug: Rilpivirine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine (25 mg once daily)
Trial: 16766777
Drug: NoExGlc -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoExGlc - Subjects consumed a 50 g glucose (glc) drink as the reference CHO for GI and insulinemic index (II) determination
Trial: 9154401
Drug: terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine (250 mg daily)
Trial: 8097683
Drug: Metoprolol (10‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (10‐15 mg plus 150 micrograms min‐1 kg‐1)
Trial: 30498827
Drug: High-protein dairy-based
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein dairy-based products and energy-enriched berry purées for three months, providing nearly 300 kcal and 14 g protein per day.
Trial: 20956208
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g TID for 2 weeks)
Trial: 18761644
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.4 U/kg) in children (8-12 years)
Trial: 18761644
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.4 U/kg) in adolescents (13-17 years)
Trial: 18761644
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.4 U/kg)
Trial: 15850630
Drug: Supervised intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised intake of artemether-lumefantrine (all doses observed with fatty-food intake; n=313)
Trial: 15850630
Drug: Unsupervised intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised intake of artemether-lumefantrine (first dose supervised followed by outpatient treatment with nutritional advice; n=644)
Trial: 12452220
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine + intravenous ketorolac
Trial: 12452220
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac alone
Trial: 10777467
Drug: Platinum-based combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based combination chemotherapy administered sequentially or concurrently with thoracic radiation therapy
Trial: 10777467
Drug: Thoracic radiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiation therapy combined with novel drugs or new drug combinations
Trial: 10777467
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and carboplatin in combination with thoracic radiation therapy
Trial: 10777467
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy with thoracic radiation therapy
Trial: 25127924
Drug: Probiotic (Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Bacillus coagulans GBI-30, 6086 capsule)
Trial: 16421034
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (lanzoprazole, clarithromycin, and amoxicillin) for 8 days
Trial: 16421034
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii plus inulin (SbI) daily for 8 weeks
Trial: 16421034
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus LB (LB) daily for 8 weeks
Trial: 14519710
Drug: CT-3 (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-3 (four 10-mg capsules per day for the first 4 days, then 8 capsules per day in 2 daily doses for the following 3 days)
Trial: 10792337
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine oestrogen (CEE)
Trial: 10792337
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg conjugated equine oestrogen (CEE)
Trial: 10792337
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg and 0.3 mg conjugated equine oestrogen (CEE)
Trial: 8785958
Drug: Diphtheria-tetanus vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus vaccine adsorbed to aluminium hydroxide
Trial: 8785958
Drug: Diphtheria-tetanus vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus vaccine adsorbed to calcium phosphate
Trial: 26967157
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who were housewives, knew three or more correct symptoms of dengue, knew at least one correct treatment for dengue, knew someone who had dengue, had children sleeping under a mosquito net, or perceived a change in mosquito amounts.
Trial: 18988089
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin cream 0.025%
Trial: 16859791
Drug: Usual dopaminergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dopaminergic treatment in PD patients
Trial: 16859791
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of dopaminergic medication in PD patients
Trial: 9361930
Drug: CsA monitoring
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA monitoring with T6 (levels obtained 6 h after the morning dose)
Trial: 9496526
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg intravenously
Trial: 26897613
Drug: Unmet information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmet information needs related to cancer/treatment
Trial: 23177487
Drug: Original clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original clopidogrel bisulphate (600 mg loading dose)
Trial: 23177487
Drug: Clopidogrel hydrochloride
RxNorm normalized name: Clopidogrel hydrochloride
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel hydrochloride (600 mg loading dose)
Trial: 23177487
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (600 mg loading dose)
Trial: 23177487
Drug: Prasugrel (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (given for 10 days after clopidogrel treatments)
Trial: 19523613
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of IM P-in-oil daily for 11 days (group 2)
Trial: 19523613
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of IM P-in-oil daily for 6 weeks (group 1)
Trial: 16855070
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg once daily, Indomethacin 50 mg twice daily
Trial: 16855070
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg, Naproxen 500 mg twice daily
Trial: 6359877
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and dipyridamole treatment
Trial: 29747292
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of renal replacement therapy (RRT) in the ELAIN trial (KDIGO stage 2 of AKI)
Trial: 29747292
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of renal replacement therapy (RRT) in the ELAIN trial
Trial: 26449391
Drug: Single-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose i.v. fosaprepitant 150 mg
Trial: 22951160
Drug: Perioperative mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative mitomycin C (MMC) instillation (40 mg MMC in 40 mL saline administered within 6 hours of surgery) followed by delayed BCG instillations (once a week for 6 weeks, 5 x 10^8 colony-forming units in 50 mL saline)
Trial: 20860912
Drug: Vildagliptin 10
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 10 mg twice daily
Trial: 20860912
Drug: Vildagliptin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 25 mg twice daily
Trial: 12882841
Drug: Insulin (premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections)
Trial: 12882841
Drug: Glibenclamide (3.5-10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (3.5-10.5 mg daily)
Trial: 12882841
Drug: Insulin (premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections) and Glibenclamide (3.5-10.5 mg daily)
Trial: 8641491
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of FSH (75 units daily)
Trial: 8641491
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage of FSH (150 units daily)
Trial: 31310319
Drug: Genetically higher
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically higher serum parathyroid hormone (S-PTH) concentrations
Trial: 9255751
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol (0.05 mg/day once a week)
Trial: 9255751
Drug: Oral norethisterone
RxNorm normalized name: ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral norethisterone acetate (NETA) 1 mg
Trial: 2893446
Drug: Naloxone 1
RxNorm normalized name: naloxone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 1 mg
Trial: 2781424
Drug: Naloxone 4
RxNorm normalized name: naloxone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 4 mg
Trial: 2893446
Drug: Timolol 2
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 2 mg
Trial: 18361004
Drug: ECMO as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECMO as rescue therapy
Trial: 16875188
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (immobilization, physiotherapy, drug therapy, steroid injections)
Trial: 12491501
Drug: L-PAM (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PAM (in premenopausal women)
Trial: 12491501
Drug: L-PAM (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PAM (in patients with > or = 4 positive lymph nodes)
Trial: 1497689
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISMN in the morning